In the United States and western Europe, lung cancer leads all other cancers in both incidence and mortality rate ( 1 ) , underscoring the need for effective lung cancer chemopreventive agents. Because tobacco smoking confers the greatest risk of developing lung cancer ( 2 ) , molecules that target pathways involved in tobacco-mediated lung carcinogenesis could be effective lung cancer chemopreventive agents. The PI3K/Akt pathway could be such a target because Akt is activated in premalignant and malignant human bronchial epithelial cells, as well as non -small-cell lung cancer cells, through the activating mutation of ras, overexpression of the epidermal growth factor receptor and subunits of PI3K, inactivation of tumor suppressor genes such as PTEN, or exposure to tobacco carcinogens, all of which are frequent events in lung cancer ( 3 -9 ) . Akt is activated by phosphorylation at two key regulatory sites, Thr 308 and Ser 473 ( 10 ) . Akt promotes cell survival by phosphorylating proapoptotic and antiapoptotic proteins, including the Bcl-2 family member BAD, caspase-9, cAMP response elementbinding protein, inhibitor of kappaB kinase complex α , and forkhead transcription factor-1 ( 11 -19 ) .
We and others have shown that pharmacologic and genetic approaches targeting Akt suppress the proliferation of premalignant and malignant human bronchial epithelial cells and reverse characteristics of transformed human bronchial epithelial cells ( 20 , 21 ) , indicating that inhibitors of Akt could be effective lung cancer chemopreventive agents. We have previously found that deguelin, isolated from several plant species, including Mundulea sericea ( Leguminosae ), inhibits the PI3K/Akt pathway and decreases the expression of cyclooxygenase-2, which participates in xenobiotic metabolism, angiogenesis, and inhibition of immune surveillance and apoptosis during tumorigenesis ( 22 ) . Importantly, deguelin induces apoptosis in premalignant and malignant human bronchial epithelial cells, with minimal effects on normal human bronchial epithelial cells in vitro at dosages attainable in vivo ( 23 ) . Deguelin has been shown to have cancer chemopreventive activities in the two-stage skin carcinogenesis model ( 24 ) and in the N-nitroso-Nmethylurea-induced rat mammary carcinogenesis model ( 25 ) . It also exhibits therapeutic activities in colon cancer, melanoma, and lung cancer ( 22 , 26 , 27 ) . These fi ndings led us to hypothesize that deguelin could be an effective lung cancer chemopreventive agent by blocking Akt activation. In the present study, we attempted to test our hypothesis in Aktinducible transgenic mice, in which Akt is activated by tamoxifen (tmaAkt/ Z;CAG::Cre) ( 28 ) , and in A/J mice, in which lung tumors are induced by 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo(a)pyrene (BaP) ( 20 , 29 ) .
To test the effects of deguelin on Akt activation in tmaAkt/Z;CAG::Cre mice, we performed immunohistochemical ( Fig. 1, A ) and immunoblot ( Fig. 1, B ) analyses with phosphorylated (p)Akt (at Ser473) on lung tissues from tmaAkt/ Z;CAG::Cre mice treated with 4 mg/kg of deguelin for 3 days. pAkt staining was homogeneous in the bronchial epithelium of the control and deguelin-treated mice; however, levels of pAkt in the lung tissues of control mice were higher than in that of deguelin-treated mice. Western blot analysis also showed decreased expression of pAkt in the lungs of deguelin-treated mice, indicating that deguelin affects Akt activation in vivo.
To evaluate the chemopreventive effects of deguelin in the A/J mice, we fi rst evaluated the serum and tissue distribution of deguelin in A/J mice. Fig. 2 , A , shows the concentration-time curve of deguelin in serum and various organs after oral gavage administration of 4 mg/kg deguelin, the maximum tolerated dose in rats ( 25 ) . The total body clearance of deguelin was 0.33 L/kg/ hour, the apparent volume of distribution was 1.86 L/kg, and the half-life was 3.98 hours. One hour after the treatment, concentrations of deguelin in various organs ranged from less than 1 ng/mL in the brain tissue to 57.1 ng/mL in the kidneys. The peak concentration in these organs occurred between 1 hour (lung, heart, and kidney) and 6 hours (liver) after administration. These studies indicate that oral deguelin administration can achieve effective absorption and distribution in several organs, including the lung.
We next tested the chemopreventive effects of deguelin in the A/J mice, in which lung carcinogenesis was induced by NNK and BaP, as previously described ( 30 ) . Cancer chemopreventive agents are classifi ed as either blocking or suppressing agents ( 31 ) . Blocking agents, which prevent the metabolic activation of carcinogens and reduce DNA damage, are tested by administering them before or simultaneously with the carcinogen. Suppressing agents, which inhibit the neoplastic progression of premalignant cells, are usually tested by administering them after the carcinogen ( 32 ) . Hence, deguelin (4 mg/kg twice a day) was administered either 1 week after the fi rst dose of NNK/BaP (entire period, group 3) or after completion of carcinogen administration (postcarcinogen, group 4) ( Fig. 2, B ) . A/J mice untreated (group 1) or treated with NNK plus BaP (group 2) received only the vehicle (corn oil) during this period. Sixteen and/or 20 weeks after the fi rst dose of NNK and BaP, representative A/J mice from groups 1, 2, and 3 were analyzed by microcomputed tomography to monitor changes in the number and size of lung tumor nodules. The lung structure in a control mouse ( Table 1 available at http://jncicancerspectrum.oxford journals.org/jnci/content/vol97/issue22 ). Deguelin-treated mice had fewer lung tumors ( Supplementary Fig. 1 and Supplementary Table 1 available at http:// jncicancerspectrum.oxfordjournals.org/ jnci/content/vol97/issue22 ); mice in groups 3 and 4 had fewer lung tumor nodules than NNK/BaP-treated mice in group 2 (mean = 4.57 versus mean = 11.0, difference = 6.43, 95% confi dence intervals , which led to the expression of inactive (not phosphorylated) Akt by excising the fl oxed CAT. Six-week-old tmaAkt/Z;CAG::Cre mice were orally treated with deguelin (4 mg/kg) during feeding twice a day for 3 days (fi ve mice/group) and then were injected intraperitoneally with 5 mg of tamoxifen (Sigma, St. Louis, MO). The next day, the mice were killed by CO 2 asphyxiation. Lungs were surgically removed, and A ) half of each lung was fi xed with 10% formaldehyde, embedded in paraffi n, sectioned (5-μ m thick), and processed for immunohistochemical analysis. The sections were deparaffi nized, immersed in methanol containing 0.3% hydrogen peroxide to block endogenous peroxidase activity, and then incubated in blocking serum (Vector Laboratories, Burlingame, CA) to reduce nonspecifi c antibody binding. The sections were incubated overnight at 4 °C with rabbit polyclonal anti-Akt (diluted 1:100 in 2.5% blocking serum) or rabbit polyclonal anti-phosphorylated Akt (pAkt, Ser473) (diluted 1:200) (Cell Signaling Technology, Beverly, MA) and were then processed using standard avidin-biotin immunohistochemical techniques according to the manufacturer's recommendations (Vector Laboratories, Burlingame, CA). Diaminobenzidine was used as a chromogen, and commercial hematoxylin was used as a counterstain. B ) The other half of each lung was lysed in 150 m M NaCl, 20 m M Tris-HCl, pH 7.5, 1% Triton X-100, 1 m M phenylmethylsulfonyl fl uoride, 10 m M EDTA, 0.1 m M vanadate, and 1 μ g/mL aprotinin by mechanical homogenization. Equivalent amounts of protein were resolved on sodium dodecyl sulfate -polyacrylamide gels (10%) and electrophoretically transferred to nitrocellulose membranes. After membranes were blocked in Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBST) and 5% (w/v) nonfat powdered milk, they were incubated with primary antibodies against pAkt (Ser473) (1:1000) and unphosphorylated Akt (1:1000) (Cell Signaling Technology, Beverly, MA) or with a goat polyclonal anti-β -Actin (1:4000) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in TBS -5% nonfat milk at 4 °C for 16 hours. The membranes were then washed three times with TBST and incubated with secondary antibody for 1 hour at room temperature. The goat anti-rabbit immunoglobulin G (IgG) or bovine anti-goat IgG horseradish peroxidase-conjugated complexes were detected using the enhanced chemiluminescence kit (Amersham, Arlington Heights, IL) according to the manufacturer's recommended protocol.
Fig. 2. Evaluation of the chemopreventive effects of deguelin in the A/J mice.
A ) Six-week-old A/J mice were given 4 mg/kg deguelin orally. The serum and indicated organ samples were collected at 0 (baseline), 1 (purple), 2 (turquoise), 4 (blue), 6 (green), 12 (brown), or 24 (orange) hours after deguelin administration. Blood samples were immediately placed on ice and centrifuged at 2000 g at 4 °C for 15 minutes, and the serum was stored at − 70 °C until analysis. The mice were killed prior to organ sample collection. Each organ sample was suspended in acetonitrile, sonicated, and then centrifuged at 1500g for 3 minutes at 4 °C. The liquid-tissue extraction process was repeated three times, and each time, 100 μ L of supernatant was collected. To the fi nal 300-μ L sample, 2700 μ L of 0.1 M ammonium acetate, pH 5.5, was added. Deguelin was isolated from both serum and organ (liquid-extracted) samples by solid-phase chromatography (tC18 solid-phase extraction [SPE] cartridge, 100 mg, Waters Corp, Millford, MA). After the SPE cartridge was conditioned with 2 mL of methanol and 2 mL of high-performance liquid chromatography-grade water, either 100 μ L of serum or 3 mL (a volume of 1 mL pulled through the column each time) of liquid-extracted sample was placed into the SPE cartridge. Deguelin was eluted with 1 mL of methanol, dried, and then reconstituted with a 100-μ L mixture of methanol and 0.1% formic acid (50:50, v/v). Thirty microliters of the reconstituted sample was then injected onto a high-performance liquid chromatography mass spectrometer (LC/MS-ES+, MicroMass, Beverly, MA). Standard calibration curves for deguelin ranged from 5 to 1000 ng/mL. The lower limit of quantitation was 0.01 ng/mL. Pharmacokinetic modeling was completed using a noncompartment method (WinNonlin version 3.1, Pharsight Corporation, Mountain View, CA). The results are expressed as means and 95% confi dence intervals (CIs), four mice/group. B -E ) Six-week-old male A/J mice (Jackson Laboratories, Bar Harbor, ME) were randomized into three groups of 12 -14 mice (groups 2 -4). We included fi ve untreated A/J mice (group 1) as a negative control. Except for group 1, all mice were treated with 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)/benzo(a)pyrene (BaP) (3 μ mol each in 0.1 mL cottonseed oil) once per week for 8 weeks by oral gavage. Vehicle (groups 1 and 2) or deguelin (groups 3 and 4) was administered by oral gavage (4 mg/kg twice a day) beginning 1 week after the fi rst dose of NNK/BaP (entire period) (group 3) or after the last dose of NNK/BaP treatment (postcarcinogen) (group 4) until the end of the experiment. The experimental design is summarized in ( B ). During the experiments, drinking water was available ad libitum, and the body weights of the mice were measured at 0, 8, and 20 weeks. Arrows indicate the time points at which microcomputed tomography (CT) image analysis was performed. C ) Registered axial respiratory-gated micro-CT image and blockfaced image analyses were performed in one of the A/J mice at 16 and 20 weeks [CIs] on the difference = 3.25 to 9.60, P = <.001 for group 3; mean = 7.60 versus mean = 11.0, difference = 3.4, 95% CIs on the difference = −0.39 to 7.19, P = .085, Fig. 2, D ) . Microscopic evaluation of the lungs revealed a statistically signifi cant decrease in tumor multiplicity, the number of tumors inside the lung (group 3: 59.4%; mean = 1.70 tumors/slide, difference = 2.48, 95% CIs on the difference = 0.97 to 4.0, P = .007; and group 4: 48.8%; mean = 2.14 tumors/slide, difference = 2.04, 95% CIs on the difference = 0.52 to 3.56, P = .046), volume (group 3: 76.1%; mean = 0.016 mm 3 , difference = 0.051, 95% CIs on the difference = 0.021 to 0.082, P = .007; and group 4: 83.58%; mean = 0.011 mm 3 , difference = 0.056, 95% CIs on the difference = 0.019 to 0.093, P = .012), and load (group 3: 89.3%; mean = 0.032 mm 3 , difference = 0.27, 95% CIs on the difference = 0.051 to 0.48, P = .009; and group 4: 92.3%; mean = 0.023 mm 3 , difference = 0.27, 95% CIs on the difference = 0.06 to 0.49, P = .006) in the deguelin-treated mice compared with the NNK/BaPtreated mice in group 2 (tumor multiplicity, mean = 4.182 tumors/slide; volume, mean = 0.067 mm 3 ; load, mean = 0.298 mm 3 ). Mice in groups 3 and 4 showed a statistically non-signifi cant decrease in body weight compared with mice in groups 1 and 2.
Immunohistochemical analysis revealed stronger cytoplasmic and nuclear pAkt staining in airway epithelial cells ( Fig. 2, E , 2 ) in mice in group 2 compared with those in group 1 ( Fig. 2, E, 1 ) and group 3 ( Fig. 2, E, 3 ). The tumors in group 2 ( Fig. 2, E, 4 ) also showed stronger pAkt staining compared with those in group 3 ( Fig. 2, E, 5 ).
In spite of its potential as a cancer chemopreventive/therapeutic agent, there is concern about possible side effects of deguelin treatment. Deguelin is derived from rotenone, which can inhibit NADH: ubiquinone oxidoreductase, an enzyme complex involved in mitochondrial oxidative phosphorylation ( 34 ) , and induce cardiotoxicity, respiratory depression, and nerve conduction blockade at high doses (a dose that is lethal to 50% of those exposed = 10 -100 g in humans). However, we did not observe major toxicity or substantial loss of body weight in the deguelin-treated A/J mice at the dose used in this study. Deguelin is also safer in terms of its mechanism of action, which differs from that of rotenone, which inhibits tubulin polymerization. Additionally, deguelin rapidly decomposes in light and air. All of these results suggest that deguelin would be harmless when orally administered. Moreover, in contrast to some natural products presently used in cancer chemoprevention and therapy, deguelin could be easily synthesized using commercially available rotenone as a starting material; therefore, its clinical use as a lung cancer chemopreventive agent is feasible. These collective fi ndings provide a strong rationale for testing deguelin in a phase I clinical trial of lung cancer chemoprevention after its complete toxicity profi le in humans is known. using a model RS-9 tabletop CT scanner (General Electric Medical Systems, London, Ontario) as previously described ( 35 , 36 ) . The technique used was 80 kVp and 450 μ A, with 720 views obtained at 0.5-degree increments at 400 msec per view. The radiation dose delivered during this scan was approximately 0.26 Gy. Labview software (National Instruments, Austin, TX) pro vided an interface for selecting the mouse respiratory parameters. The Feldkamp reconstruction method was used to normalize the raw images and to correct for nonuniformities in the detector ( 35 ) . Images were formed with isotropic 91-mm voxels. NNK/BaP-treated mice sections ( 10 ) were fast-frozen immediately after their micro-CT scan session to confi rm their position in the images relative to block-faced pathologic sections. A representative micro-CT ( 1, 2, 4 -7 ) or blockfaced ( 3 ) image analysis of the lungs from a control mouse ( 1 ) or mice treated with NNK/BaP alone ( 2 -5 ) or with NNK/BaP plus deguelin (group 3) at 16 ( 4, 6 ) and 20 ( 5, 7 ) weeks is shown. l = lung; e = esophagus; v = thoracic vertebra; L = liver; s = spinal cord. D ) Postmortem examinations were performed on the lungs of the A/J mice after mice were killed at 20 weeks. The lung tissues were fi xed in Bouin's solution, and the gross tumor nodules (lung tumors/slide) were counted. Microscopic evaluation of lung tissues was also performed to measure mean tumor number (N), volume (V), and total tumor load (N × V) in a blinded fashion. The tumor volume was calculated by the formula of V (mm 3 ) = (long diameter × short diameter 2 )/2. The number and size of tumors in fi ve sections distributed uniformly through each lung were calculated. Body weight of the mice was measured at 0 (baseline), 8, and 20 weeks (wks). Effects of deguelin on lung tumorigenesis were expressed by means and 95% CIs of tumor nodules/mouse, tumor nodules/slide (multiplicity), volume, and load from 12 (group 2) or 14 (groups 3 and 4) samples. The data were analyzed in comparision with that from the mice treated with NNK/BaP (group 2). We set values from group 2 at 100% and then calculated the others as a percentage of that. Differences between groups were compared using the t test or Mann-Whitney statistical test. Differences were considered statistically signifi cant if P < .05. Histopathologic evidence of pulmonary toxicity, i.e., edema or infl ammation of the bronchial epithelium and alveoli and infl ammation and injury in other organs were evaluated by a veterinary pathologist. These animal studies were approved by M. D. Anderson Cancer Center's Institutional Animal Care and Use Committee. E ) After the evaluation of tumor nodules, lung tissues were surgically removed and paraffi n embedded. Bronchial epithelium ( 1, 2, 3 ) and lung adenoma ( 4, 5 ) lesions in the A/J mice that were untreated ( 1 ) or treated with NNK/BaP alone ( 2, 4 ) or NNK/BaP plus deguelin ( 3, 5 ) were processed for immunohistochemical analysis with anti-pAkt (Ser473) as described in Fig. 1 .
